<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="4" ids="30413">Heme</z:chebi> oxygenase-1 knockout, H(mox)1(-/-), mice exhibit exacerbated vascular lesions after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion and mechanical injury </plain></SENT>
<SENT sid="1" pm="."><plain>Surprisingly, we found no studies that reported contractile responses and sensitivity to vasorelaxants in H(mox)1(-/-) mice </plain></SENT>
<SENT sid="2" pm="."><plain>The contractile responses [superior mesenteric arteries (SMA), from female H(mox)1(-/-) mice] exhibited increased sensitivity to <z:chebi fb="0" ids="8093">phenylephrine</z:chebi> (p &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Cumulative addition of <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> relaxed SMA, with the residual contraction remaining 2 times higher in H(mox)1(-/-) mice (p &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="29321">Sodium nitroprusside</z:chebi> (SNP, an NO donor) and 3-(5'-<z:chebi fb="0" ids="24712">hydroxymethyl</z:chebi>-2'-furyl)-1-<z:chebi fb="0" ids="22744">benzyl</z:chebi> <z:chebi fb="0" ids="36669,36671">indazole</z:chebi> [YC-1; acts directly on soluble guanylate cyclase (sGC)] led to further relaxation, yet the residual contraction remained 2 to 3 times higher in H(mox)1(-/-) than H(mox)1(+/+) mice (p &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Branches from H(mox)1(-/-) mesenteric and renal arteries also showed reduced relaxation (p &lt; 0.025) </plain></SENT>
<SENT sid="6" pm="."><plain>Relaxation of SMA was measured to 4-({(4-carboxybutyl) [2-(5-fluoro-2-{[4'-(<z:chebi fb="0" ids="50127">trifluoromethyl</z:chebi>) <z:chebi fb="0" ids="35447">biphenyl-4-yl</z:chebi>] <z:chebi fb="8" ids="32772">methoxy</z:chebi>}<z:chebi fb="1" ids="30396">phenyl</z:chebi>)ethyl]amino}<z:chebi fb="0" ids="30746">benzoic acid</z:chebi> (BAY 60-2770), which is a more effective activator of oxidized/<z:chebi fb="4" ids="30413">heme</z:chebi>-free sGC; and to 5-<z:chebi fb="0" ids="30364">cyclopropyl</z:chebi>-2-{1-(2-fluoro-<z:chebi fb="0" ids="22744">benzyl</z:chebi>)-1H-pyrazolo[3,4-b]<z:chebi fb="0" ids="51642">pyridin-3-yl</z:chebi>}-<z:chebi fb="0" ids="38616">pyrimidin-4-ylamine</z:chebi> (BAY 41-2272), a more effective stimulator of reduced sGC </plain></SENT>
<SENT sid="7" pm="."><plain>H(mox)1(-/-) arteries were 15 times more sensitive to BAY 60-2770 (p &lt; 0.025) than were H(mox)1(+/+) arteries </plain></SENT>
<SENT sid="8" pm="."><plain>Pretreatment with <z:chebi fb="8" ids="29300">1H-</z:chebi>[1,2,4]oxadiazolo[3,4-a]quinoxalin-1-one (ODQ), an oxidizer of sGC, predictably shifted the BAY 60-2770 response of H(mox)1(+/+) to the left (p &lt; 0.01) and BAY 41-2272 response to the right (p &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>ODQ had little effect on the responses of H(mox)1(-/-) arteries, indicating that much of sGC was oxidized/<z:chebi fb="4" ids="30413">heme</z:chebi>-free </plain></SENT>
<SENT sid="10" pm="."><plain>Western analyses of sGC in SMA indicated that both α1 and β1 subunit levels were reduced to &lt;50% of H(mox)1(+/+) level (p &lt; 0.025) </plain></SENT>
<SENT sid="11" pm="."><plain>These findings support the hypothesis that the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> function of H(mox)1 plays a significant role in the maintenance of sGC in a reduced state, which is resistant to degradation and is sensitive to NO </plain></SENT>
<SENT sid="12" pm="."><plain>This function may be especially important in reducing vascular damage during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury </plain></SENT>
</text></document>